Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Revance Therapeutics, Inc. | Director | Common Stock | 31.6K | $120K | $3.80 | May 1, 2024 | Direct |
Revance Therapeutics, Inc. | Director | Stock Option (Right to buy) | 23.5K | May 1, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
RVNC | Revance Therapeutics, Inc. | May 1, 2024 | 2 | $0 | 4 | May 3, 2024 | Director |
RVNC | Revance Therapeutics, Inc. | Jun 15, 2023 | 3 | -$25.3K | 4 | Jun 20, 2023 | Director |
RVNC | Revance Therapeutics, Inc. | May 3, 2023 | 2 | $0 | 4 | May 5, 2023 | Director |
RVNC | Revance Therapeutics, Inc. | May 4, 2022 | 1 | $0 | 4/A | May 13, 2022 | Director |
RVNC | Revance Therapeutics, Inc. | May 5, 2021 | 2 | $0 | 4 | May 7, 2021 | Director |